Response to comment on ‘SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung’

Journal Article · Tue Jan 11 00:00:00 EST 2022 · eLife

DOI:https://doi.org/10.7554/eLife.74951· OSTI ID:1855666

Jacobson, Daniel A. ^[1]; Mast, Alan Mast ^[2]; Wolberg, Alisa S. ^[3]; Gailani, David ^[4]; Garvin, Michael R. ^[1]; Jones, Piet C. ^[5]; Alvarez, Christiane ^[1]; Miller, John Izaak ^[1]; Aronow, Bruce ^[6]

---

1. Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States)
2. Univ. of Wisconsin, Milwaukee, WI (United States)
3. Univ. of North Carolina, Chapel Hill, NC (United States)
4. Vanderbilt Univ., Nashville, TN (United States)
5. Univ. of Tennessee, Knoxville, TN (United States)
6. Univ. of Cincinnati, OH (United States)

Early in the SARS-CoV-2 pandemic, we compared transcriptome data from hospitalized COVID-19 patients and control patients without COVID-19. We found changes in procoagulant and fibrinolytic gene expression in the lungs of COVID-19 patients. These findings have been challenged based on issues with the samples. We have revisited our previous analyses in the light of this challenge and find that these new analyses support our original conclusions.

• Research Organization: Oak Ridge National Laboratory (ORNL), Oak Ridge, TN (United States)
• Sponsoring Organization: Bayer; Bristol Myers Squibb; Novo Nordisk; USDOE
• Grant/Contract Number: AC05-00OR22725
• OSTI ID: 1855666
• Journal Information: eLife, Journal Name: eLife Journal Issue: na Vol. 11; ISSN 2050-084X
• Publisher: eLife Sciences Publications, Ltd.
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES